Table 1.
Baseline Characteristics, Medical History, Presentation, and Outcomes of the Included 3 307 703 Patients With MI Stratified According the Presence of Psoriasis
| Parameters |
Patients With MI With Psoriasis (n=9028; 0.3%) |
Patients With MI Without Psoriasis (n=3 298 675; 99.7%) |
P Value |
|---|---|---|---|
| Age | 68.0 (58.0–76.0) | 73.0 (62.0–81.0) | <0.001* |
| Age >70 y, n (%) | 3791 (42.0) | 1 875 095 (56.8) | <0.001* |
| Female sex,† n (%) | 2795 (31.0) | 1 240 241 (37.6) | <0.001* |
| In‐hospital stay, d | 9 (5–15) | 7 (4–13) | <0.001* |
| Traditional cardiovascular risk factors, n (%) | |||
| Obesity | 1618 (17.9) | 305 473 (9.3) | <0.001* |
| Smoking | 1290 (14.3) | 242 814 (7.4) | <0.001* |
| Essential arterial hypertension | 5316 (58.9) | 1 813 227 (55.0) | <0.001* |
| Hyperlipidemia | 4005 (44.4) | 1 273 037 (38.6) | <0.001* |
| Diabetes mellitus | 3143 (34.8) | 1 004 183 (30.4) | <0.001* |
| Myocardial infarction subtype, n (%) | |||
| STEMI | 3047 (33.6) | 1 146 793 (34.7) | 0.037 |
| NSTEMI | 5539 (61.4) | 2 003 161 (60.7) | 0.223 |
| Myocardial infarction without coded STEMI/NSTEMI subclassification | 442 (5.0) | 148 721 (4.6) | |
| Comorbidities | |||
| Charlson Index | 2 (1–5) | 2 (1–4) | <0.001* |
| Peripheral artery disease, n (%) | 818 (9.1) | 212 415 (6.4) | <0.001* |
| Cancer, n (%) | 345 (3.8) | 123 175 (3.7) | 0.662 |
| Atrial fibrillation/flutter, n (%) | 2060 (22.8) | 717 177 (21.7) | 0.013* |
| Chronic obstructive pulmonary disease, n (%) | 1169 (12.9) | 293 956 (8.9) | <0.001* |
| Sleep apnea, n (%) | 229 (2.5) | 38 945 (1.2) | <0.001* |
| Renal insufficiency (glomerular filtration rate <60 mL/min per 1.73 m2), n (%) | 1423 (15.8) | 497 139 (15.1) | 0.067 |
| Interventional treatments, n (%) | |||
| Cardiac catheter | 4960 (54.9) | 1 821 679 (55.2) | 0.587 |
| Percutaneous coronary intervention | 3737 (41.4) | 1 386 343 (42.0) | 0.223 |
| Bare metal stent | 1501 (16.6) | 577 806 (17.5) | 0.026* |
| Drug eluting stent | 2041 (22.6) | 730 316 (22.1) | 0.285 |
| Bioresorbable vascular scaffold | 27 (0.3) | 8295 (0.3) | 0.367 |
| Coronary artery bypass graft | 697 (7.7) | 153 419 (4.7) | <0.001* |
| Adverse events during hospitalization, n (%) | |||
| In‐hospital death | 640 (7.1) | 410 097 (12.4) | <0.001* |
| Recurrent myocardial infarction | 72 (0.80) | 21 522 (0.65) | 0.087 |
| Pneumonia | 1143 (12.7) | 383 522 (11.6) | 0.002* |
| Deep venous thrombosis or thrombophlebitis | 86 (1.0) | 22 399 (0.7) | 0.002* |
| Pulmonary embolism | 68 (0.8) | 22 588 (0.7) | 0.431 |
| Acute kidney injury | 554 (6.1) | 206 296 (6.3) | 0.645 |
| Shock | 495 (5.5) | 227 615 (6.9) | <0.001* |
| Stroke (ischemic or hemorrhagic) | 259 (2.9) | 95 105 (2.9) | 0.935 |
| Intracerebral bleeding | 37 (0.4) | 9373 (0.3) | 0.025* |
| Subarachnoid bleeding | 6 (0.1) | 2824 (0.1) | 0.717 |
| Gastrointestinal bleeding | 132 (1.5) | 47 754 (1.4) | 0.909 |
| Transfusion of blood constituents | 1383 (15.3) | 419 208 (12.7) | <0.001* |
| Pericardial effusion | 76 (0.8) | 21 262 (0.6) | 0.019* |
NSTEMI indicates non–ST‐segment–elevation myocardial infarction; and STEMI, ST‐segment–elevation myocardial infarction.
*
P values of <0.05 (two‐sided) were considered to be statistically significant.
†
Information available for 3 307 574 patients.